Transdermal (standard strength) combined hormonal contraceptives (Formulary)

EVRA®

Important: Therapy notes

  • The Scottish Medicines Consortium accepts the use of Evra®only in those patients where non-compliance with oral therapies is proven.

Important: Formulation and dosage details

Formulation:

Patches (releasing ethinylestradiol approximately 33·9 micrograms/24 hours and norelgestromin approximately 203 micrograms/24 hours) (s)

Editorial Information

Document Id: F376